###### Strengths and limitations of this study

-   This is the first study that fully reports on characteristics at admission as well as the short-term and mid-term outcomes of patients with coronary artery disease (CAD) in Indonesia.

-   We completed, to the best of our ability, the follow-up of this study by actively visiting patients' houses or contacting their family members to obtain outcomes data.

-   Diversity on places of origin in our cohort represents the population in Indonesia, and generally represents a population in South-East Asia with limited resources.

-   Due to geographical and distance constraints, follow-up was completed by telephone in half of this cohort.

-   We excluded all patients with normal coronary angiography, and therefore our study might overlook the minor group of non-obstructive CAD.

Introduction {#s1}
============

The South-East Asia region, which accounts for one-quarter of the world's population and 40% of the global poor, is facing a rapid epidemiological transition.[@R1] This leads to the high rates of premature death from non-communicable diseases (NCD), primarily from cardiovascular disease (CVD).[@R2] Of the 7.9 million annual NCD in this region, 34% occur before the age of 60 years compared with 16% in the European region and 23% in the rest of the world.[@R2] Half of the world's cardiovascular burden is estimated to occur in Asia,[@R3] and the prevalence of symptomatic heart failure appears to be higher in South-East Asia countries compared with the rest of the world.[@R4] Despite the high burden of CVD in South-East Asia, little is known about characteristics at admission and clinical outcomes in patients with coronary artery disease (CAD), especially acute coronary syndrome (ACS).

Recent studies indicate the insufficient access to evidence-based interventions for combating CVD in low-income and middle-income countries.[@R5] Particularly in Indonesia, the population of 260 million and a unique demographic situation (consisting of 17 508 islands, over 6000 are inhabited) aggravate the inequity in the access to healthcare services, not only between the the rich and the poor, but also between rural and urban population within the country. Logistics and financial shortcomings,[@R7] as well as the low awareness of the symptoms[@R6] associated with CVD in these populations---resulted in delayed diagnosis and a younger age of death from CVD compared with the Western world.[@R8] In Indonesia, there were approximately 760 cardiologists[@R9] and only 70 certified interventional cardiologists[@R10] available to serve 883 447 patients diagnosed with CAD and approximately 2 650 340 patients suspected with CAD in 2013.[@R11] However, half of these cardiologists work on Java island and in the big cities, leaving other regions even less well served.[@R9]

Besides the centralisation of healthcare facilities and the lack of healthcare professionals, 94.1% of households in 18 provinces in Indonesia are located more than 5 km from any primary healthcare centre or hospital[@R12] with very minimal means of transportation and infrastructure. In addition, 28.6 million people (11.2% of total population) are living at poor socioeconomic levels,[@R13] and the majority were insufficiently health insured until 2013.[@R7] Despite the fact that CVD ranks as the top cause of mortality in Indonesia, any follow-up studies of hospitalised patients with CAD (ACS and stable CAD (SCAD)) are rare.

Thus, in Indonesia there is clearly a general problem with access to care, but possibly also with the quality of care. It is suspected that many hospitalised patients who should be considered for early invasive strategy actually encounter delayed or overly conservative approaches. We studied the characteristics and clinical profiles of patients with CAD presenting at the Makassar Cardiac Center, Indonesia. These patient outcomes were evaluated in hospital, at 30 days and at 6 months.

Methods {#s2}
=======

Study population {#s2a}
----------------

This was an observational cohort study of 477 consecutive patients who presented between February 2013 and December 2014 with a diagnosis of CAD at the Makassar Cardiac Center, Wahidin Sudirohusodo Hospital, one of the two public cardiac referral centres in East Indonesia. The cardiac centre with seven cardiologists mainly serves the 9.5 million South Sulawesi population, and also other regions inside and outside Sulawesi island.

Patients were included if they had confirmed CAD, defined as ACS and SCAD. ACS was defined as a spectrum of clinical presentations consistent with acute cardiac ischaemia within 24 hours of hospital presentation, including unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) and STEMI.[@R14] SCAD was defined as at least one of the following criteria: stable angina, history of UA, prior MI, prior coronary revascularisation (percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG)), or multivessel CAD without revascularisation.[@R16] All eligible patients signed written informed consent before the first interview. We excluded all fatal patients who immediately died at the emergency department or cardiovascular intensive care unit before being able to give informed consent, and all suspected patients with normal coronary angiography (CAG) (defined as 0% lumen stenosis in all coronary vessels).[@R17] The flow chart of the study population is presented in [figure 1](#F1){ref-type="fig"}.

![Flow chart of the study population. ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, congestive heart failure; CVD, cardiovascular disease; HF, heart failure; RSWS: Rumah Sakit Wahidin Sudirohusodo (Wahidin Sudirohusodo hospital).](bmjopen-2018-021996f01){#F1}

Data collection and follow-up {#s2b}
-----------------------------

At hospital admission, we obtained baseline data from medical records and questionnaire interviews. Data on sociodemographic characteristics included age, gender, occupation, living area, monthly income and educational level; lifestyle included smoking status, dietary pattern and physical activity; family history of CVD included family history of premature sudden death at age \<60 years[@R18]; clinical profiles included characteristics and onset of chest pain, previous medications, as well as history of previous diseases (ie, hypertension, type 2 diabetes mellitus, MI, stroke and kidney disease). Detailed methods were presented as online [supplementary material](#SP1){ref-type="supplementary-material"}.
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Clinical data were collected prospectively at the time of hospital admission based on physical examination including vital signs, anthropometric measurements (ie, height, weight and waist circumference), electrocardiography, echocardiography including left ventricular ejection fraction (LVEF), CAG, laboratory tests including cardiac enzymes and estimated glomerular filtration rate. In-hospital managements and at-discharge medications were also recorded. Plasma glucose, lipid profiles, uric acid, renal and liver functions were measured within 24 hours of hospital admission following a minimum 8 hours fast for all patients hospitalised at Wahidin Sudirohusodo Hospital. While, for patients who were referred from other hospitals or clinics (n=70), we obtained baseline and laboratory data from their medical records. All blood samples analyses were generated with standardised methods at the hospital laboratory.

Furthermore, data on mortality and major adverse cardiovascular events (MACE) were obtained during hospitalisation, at 30 days and at 6 months after hospital admission. For referred patients, we obtained data on in-hospital mortality from their family members and this was confirmed with hospital medical records from where the patients were admitted (n=1). We actively performed the follow-up by visiting patient's houses or by an interview via telephone. The nurses asked a detailed questionnaire about patient's current condition, cardiovascular complaints, rehospitalisation, deaths and other CVD-related events from the patients, family members or their relatives. Subsequently, we verified their answers with the medical records in hospital, or with the patient's documentation at home.

Study outcomes {#s2c}
--------------

The primary endpoints of our study were the rates of in-hospital, 30-day and 6-month all-cause mortality and composite MACE. The composite MACE counting for cardiac and non-cardiac death, MI rehospitalisation, heart failure requiring hospitalisation, rehospitalisation due to stroke, (emergency) CABG, stent thrombosis, repeat PCI, repeat CAG, first PCI and first CAG.

Statistical analysis {#s2d}
--------------------

Continuous variables were presented as mean±SD, and categorical variables as number (percentage). Skewed data were provided as median (Q1--Q3). Baseline characteristics, clinical profiles and managements during hospitalisation were divided into acute (ACS) and non-acute (SCAD) groups. The rates of mortality and composite MACE in hospital, at 30 days and at 6 months after hospital admission were calculated. Kaplan-Meier curves were used to describe the cumulative survival during 6-month follow-up. Log rank statistics were used to assess the difference between guideline-treated and non-guideline-treated groups. A 95% CI not including one, corresponding to a two-sided p\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS V.23.0.

Patient involvement {#s2e}
-------------------

Patients were not involved in the design and development of the research questions. The results of this study are used to provide information for the stakeholders and health-policy makers to improve healthcare services in Indonesia. Therefore, the findings of our study were not disseminated directly to all participants.

Results {#s3}
=======

Among 477 patients hospitalised with CAD, 257 (53.9%) were at young age (\<60 years),[@R19] and 347 (72.7%) were male.

[Table 1](#T1){ref-type="table"} shows the baseline characteristics of patients with CAD. As presented, patients with CAD in Indonesia had high levels of systolic blood pressures, fasting plasma glucose and low-density lipoprotein (LDL) cholesterol, and low level of high-density lipoprotein cholesterol. More than half of these patients had metabolic syndrome but did not have central obesity. Most came from rural areas and from low and middle socioeconomic status, more often were current or former smokers, had poor dietary habits with high consumption of sugar and deep fried food, and had low physical activity. The clinical profiles at hospital admission are presented in [table 2](#T2){ref-type="table"}. Of all patients, 75.1% had previous hypertension, 34.4% had previous MI and 7.5% had a previous stroke. Patients diagnosed with STEMI, NSTEMI, UA and SCAD were 44.2%, 17.8%, 14.3% and 23.7%, respectively. At hospital admission, 30.8% of patients had diabetes mellitus, 38.6% were diagnosed or presented with heart failure signs and 31.2% had reduced renal function. Out of 273 patients with CAG, 169 (61.9%) had multivessel disease. Among 262 (54.9%) patients who underwent echocardiography, 24.0% had an LVEF ≤35%.

###### 

Baseline characteristics at hospital admission

  Variables                              ACS              SCAD             Total            P values
  -------------------------------------- ---------------- ---------------- ---------------- ----------
  Age (years)                            57.5±11.2        60.6±8.8         58.2±10.8        0.007
  Male                                   260 (71.4)       87 (77.0)        347 (72.7)       0.246
  Systolic BP (mm Hg)                    130.0±27.6       127.3±20.4       129.4±26.1       0.336
  Diastolic BP (mm Hg)                   82.7±16.1        80.8±10.3        82.2±14.9        0.228
  Fasting plasma glucose (mmol/L)\*      7.3 (5.8--9.6)   5.9 (5.1--8.2)   7.0 (5.7--9.1)   \<0.001
  Total cholesterol (mmol/L)\*           5.0 (4.2--5.7)   5.1 (3.7--5.6)   5.0 (4.1--5.7)   0.233
  Triglycerides (mmol/L)\*               1.4 (1.1--1.9)   1.5 (1.0--1.9)   1.5 (1.1--1.9)   0.654
  HDL-chol (mmol/L)                      0.95±0.31        0.92±0.35        0.94±0.32        0.456
  LDL-chol (mmol/L)\*                    3.3 (2.6--4.0)   3.2 (2.3--3.7)   3.3 (2.6--3.9)   0.032
  Waist circumference (cm)               84.6±7.4         84.9±6.1         84.6±7.1         0.666
  Obese (BMI ≥25 kg/m^2^)                119 (32.7)       46 (40.7)        165 (34.6)       0.118
  Metabolic syndrome†                    208 (57.1)       56 (49.6)        264 (55.3)       0.157
  Parental history of CVD‡               95 (26.1)        27 (23.9)        122 (25.6)       0.639
  Monthly income ≥Rp1 810 000§           155 (42.6)       74 (65.5)        229 (48.0)       \<0.001
  College education                      134 (36.8)       55 (48.7)        189 (39.6)       0.024
  Living \>20 km from hospital (rural)   193 (53.0)       54 (47.8)        247 (51.8)       0.331
  Funding/insurance                                                                         
   Private fund (high income)            30 (8.2)         6 (5.3)          36 (7.5)         0.303
   Jamsostek (company)¶                  10 (2.7)         0 (0.0)          10 (2.1)         0.127
   Askes (middle income)                 144 (39.6)       97 (85.8)        241 (50.5)       \<0.001
   Jamkesmas/Jamkesda (low income)       107 (29.4)       8 (7.1)          115 (24.1)       \<0.001
   BPJS (national)\*\*                   73 (20.1)        2 (1.8)          75 (15.7)        \<0.001
  Current smoker                         103 (28.3)       20 (17.7)        123 (25.8)       0.024
  Former smoker                          118 (32.4)       56 (49.6)        174 (36.5)       0.001
  Physical inactivity                    218 (59.9)       59 (52.2)        277 (58.1)       0.148
  High-sugar intake                      202 (55.5)       46 (40.7)        248 (52.0)       0.006
  High-salty food and MSG intake         148 (40.7)       33 (29.2)        181 (37.9)       0.028
  High-fried food intake                 221 (60.7)       68 (60.2)        289 (60.6)       0.919
  Often reuse cooking oil                190 (52.2)       29 (25.7)        219 (45.9)       \<0.001

Values are n (%) or means±SD, unless otherwise stated. Comparison of baseline characteristics was performed using independent-samples t-test for continuous variables and Pearson χ^2^ test for categorical variables.

\*Values are medians (Q1--Q3). Comparison was performed using Mann-Whitney U test.

†Metabolic syndrome was defined using National Cholesterol Education Program Adult Treatment Panel III classification.

‡Parental history of CVD was positive, if patients have had either mother with CVD at the age under 65 years, or father with CVD at the age under 55 years, or second degree of family with history of premature sudden cardiac death.

§US\$1=Rp13 500 (Indonesian Rupiah). The cut-point based on the national average of decent-living minimum income in 2015.

¶Comparison was done using Fisher's exact test.

\*\*As a national health insurance, BPJS has been started since 1 January 2014.

ACS, acute coronary syndrome; Askes, asuransi kesehatan (civil servant insurance); BMI, body mass index; BP, blood pressure; BPJS, badan penyelanggara jaminan sosial (national insurance); CVD, cardiovascular disease; HDL-chol, high-density lipoprotein cholesterol; Jamkesda, jaminan kesehatan daerah (local insurance for poor people); Jamkesmas, jaminan kesehatan masyarakat (national insurance for poor people); Jamsostek, jaminan sosial tenaga kerja (company insurance); LDL-chol, low-density lipoprotein cholesterol; MSG, mono-sodium glutamate; SCAD, stable coronary artery disease.

###### 

Clinical presentation at hospital admission[@R1]

  Variables                        ACS                  SCAD                 Total                P values
  -------------------------------- -------------------- -------------------- -------------------- ----------
  Prehospital                                                                                     
   Previous hypertension           268 (73.6)           90 (79.6)            358 (75.1)           0.196
   On medication of hypertension   156 (42.9)           55 (48.7)            211 (44.2)           0.277
   Previous MI                     126 (34.6)           38 (33.6)            164 (34.4)           0.847
   Previous stroke                 27 (7.4)             9 (8.0)              36 (7.5)             0.848
   Previous CAG                    48 (13.2)            21 (18.6)            69 (14.5)            0.154
   Previous PCI                    14 (3.8)             13 (11.5)            27 (5.7)             0.002
  In hospital                                                                                     
   STEMI                           211 (58.0)           NA                   211 (44.2)           NA
   NSTE-ACS                        153 (42.0)           NA                   153 (32.1)           NA
   Diabetes mellitus               112 (30.8)           35 (31.0)            147 (30.8)           0.967
   With HF diagnosis/signs         150 (41.2)           34 (30.1)            184 (38.6)           0.034
   Atrial fibrillation\*           9 (2.5)              3 (2.7)              12 (2.5)             1.000
   Left ventricle hypertrophy      124 (34.1)           21 (18.6)            145 (30.4)           0.002
   Echocardiography assessed       210 (57.7)           52 (46.0)            262 (54.9)           0.029
   LVEF (%)                        45±13.2              49.3±17.4            45.8±14.2            0.049
   Troponin T (μg/L)†              0.42 (0.10-1.58)     0.00 (0.00-0.02)     0.20 (0.02--1.00)    \<0.001
   Haemoglobin (g/dL)              13.6±2.1             13.5±2.1             13.6±2.1             0.61
   Haematocrit                     0.40±0.06            0.41±0.14            0.40±0.09            0.296
   Creatinine (μmol/L)†            88.4 (79.6--114.9)   88.4 (77.8--114.9)   88.4 (79.6--114.9)   0.869
   eGFR \< 60 mL/min               108 (29.7)           41 (36.3)            149 (31.2)           0.185
  Comorbidities                                                                                   
   Concomitant stroke\*            18 (4.9)             3 (2.7)              21 (4.4)             0.3
   With cardiogenic shock\*        17 (4.7)             0 (0.0)              17 (3.6)             0.017
   Concomitant pneumonia           37 (10.2)            5 (4.4)              42 (8.8)             0.06
  VD                                                                                              
   Non-significant 1 - 2 VD‡       27 (7.4)             12 (10.6)            39 (8.2)             0.666
   1 VD                            45 (12.4)            20 (17.7)            65 (13.6)            0.738
   2 VD                            30 (8.2)             15 (13.3)            45 (9.4)             0.954
   3 VD                            53 (14.6)            41 (36.3)            94 (19.7)            0.007
   \> 3 VD\*                       28 (7.7)             2 (1.8)              30 (6.3)             0.001

Values are n (%) or means ±SD, unless otherwise stated. Comparison was performed using independent-samples t-test for continuous variables and Pearson χ^2^ test for categorical variables.

\*Comparison was done using Fisher's exact test.

†Values are medians (Q1--Q3). Comparison was done using Mann-Whitney U test.

‡Defined as 1%--49% lumen stenosis in at least one coronary vessel.[@R17]

ACS, acute coronary syndrome; CAG, coronary angiography; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NSTE, non-ST-elevation; PCI, percutaneous coronary intervention; SCAD, stable coronary artery disease; STEMI, ST-segment elevation myocardial infarction; VD, vessel disease.

[Table 3](#T3){ref-type="table"} summarises invasive and pharmacotherapy managements during hospitalisation. Of 211 patients with STEMI, only 10 (4.7%) underwent primary PCI and 13 (6.2%) received thrombolysis for early reperfusion. Meanwhile, of 477 patients, 42.8% had no exploration of CAG, and 19.1% underwent either PCI or CABG for revascularisation. Overall, there was a 24--36 hours time lapse between angina onset and hospital admission in ACS and SCAD groups, respectively (p=0.002). Patients with stable disease (SCAD) stayed shorter in hospital compared with patients with ACS (p\<0.001).

###### 

Managements in hospital from admission to 6 months

  Variables                           ACS            SCAD            Total           P values
  ----------------------------------- -------------- --------------- --------------- ----------
  Onset to admission (hours)          24 (9--48)     36 (16.3--72)   26.8 (10--48)   0.002
  Length of hospitalisation (days)    7 (5--10)      1 (0--7)        6 (4--9)        \<0.001
  Admission to intervention (hours)   120 (8--168)   8 (4--149.6)    96 (8--149.6)   \<0.001
  Invasive treatment                                                                 
   Thrombolysis                       13 (3.6)       NA              13 (2.7)        NA
   Primary PCI                        10 (2.7)       NA              10 (2.1)        NA
   Elective PCI                       47 (12.9)      32 (28.3)       79 (16.6)       0.003
   CABG+PCI\*                         2 (0.5)        0 (0.0)         2 (0.4)         1
   CAG only                           124 (34.1)     58 (51.3)       182 (38.2)      0.001
   No exploration                     181 (49.7)     23 (20.4)       204 (42.8)      \<0.001
  Pharmacotherapy                                                                    
   Anticoagulant                      168 (46.2)     16 (14.2)       184 (38.6)      \<0.001
   ASA                                320 (87.9)     74 (65.5)       394 (82.6)      \<0.001
   Clopidogrel                        308 (84.6)     58 (51.3)       366 (76.7)      \<0.001
   Statin                             271 (74.5)     54 (47.8)       325 (68.1)      \<0.001
   Hypertension medication            263 (72.3)     80 (70.8)       343 (71.9)      0.123

Values are n (%) and medians (Q1--Q3). Comparison was done using Mann-Whitney U test for continuous variables and Pearson χ^2^ test for categorical variables.

\*Comparison was done using Fisher's exact test.

ACS, acute coronary syndrome; ASA, acetylsalicylic acid; CABG, coronary artery bypass graft surgery; CAG, coronary angiography; NA, not applicable; PCI, percutaneous coronary intervention; SCAD, stable coronary artery disease.

[Figure 2](#F2){ref-type="fig"} describes the clinical outcomes at 30-day and 6-month follow-up. More patients with ACS died during hospitalisation compared with SCAD (12.6% vs 5.3%, p=0.029). However, these SCAD group experienced 6-month adverse cardiovascular events more frequently compared with ACS group (25.7% vs 15.7%, p=0.043). The rates of all-cause mortality in hospital, at 30 days and at 6 months were 10.9%, 2.5%, and 7.3%, respectively. In total, 189 (39.6%) participants experienced at least one adverse event during the study period. A detailed description of MACE at 30 days and 6 months of these CAD patients is presented in [table 4](#T4){ref-type="table"}.

![Clinical outcomes at 30-day and 6-month follow-up. ACS, acute coronary syndrome; MACE, major adverse cardiovascular events; SCAD, stable coronary artery disease.](bmjopen-2018-021996f02){#F2}

###### 

MACE during follow-up

  Composite MACE            At 30 days   At 6 months   Total
  ------------------------- ------------ ------------- ------------
  All-cause mortality       64 (13.4)    35 (7.3)      99 (20.8)
  MI rehospitalisation      14 (2.9)     23 (4.8)      37 (7.8)
  HF rehospitalisation      1 (0.2)      6 (1.3)       7 (1.5)
  Stroke                    2 (0.4)      4 (0.8)       6 (1.3)
  Emergency CABG            1 (0.2)      1 (0.2)       2 (0.4)
  Repeat PCI                5 (1.0)      3 (0.6)       8 (1.7)
  Repeat CAG                3 (0.6)      5 (1.0)       8 (1.7)
  First PCI postdischarge   23 (4.8)     3 (0.6)       26 (5.5)
  First CAG postdischarge   11 (2.3)     6 (1.3)       17 (3.6)
  Stent thrombosis          1 (0.2)      0 (0.0)       1 (0.2)
  Total MACE                125 (26.2)   86 (18.0)     211 (44.2)

Values are n (%).

CABG, coronary artery bypass graft surgery; CAG, coronary angiography; HF, heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Seven (1.5%) participants were lost to follow-up. At 6 months, the survival rate was 78.9%. The Kaplan-Meier curves showed significantly better survival in patients with statin (p=0.002), clopidogrel (p\<0.001) and revascularisation (PCI/CABG) groups (p=0.001) compared with the respective counterparts. In subgroup analysis, patients with ACS and SCAD without PCI/CABG had the worst survival rates compared with those with revascularisation (p=0.002) ([figure 3](#F3){ref-type="fig"}). Description of the most notable complaints or symptoms reported by all survivors is provided as online [supplementary material](#SP1){ref-type="supplementary-material"}.

![Kaplan-Meier curves for cumulative 6-month survival, comparing the guideline-treated versus non-guideline-treated groups in all participants and between diagnosis groups. Comparison was performed using LR (Mantel-Cox) test. ACS, acute coronary syndrome; CABG, coronary artery bypass graft surgery; LR, log rank; PCI, percutaneous coronary intervention; SCAD, stable coronary artery disease.](bmjopen-2018-021996f03){#F3}

Discussion {#s4}
==========

The present study shows that patients with CAD in Indonesia are predominantly young males with high prevalence of cardiovascular risk factors. More than half of this cohort had metabolic syndrome and prior hypertension; and approximately one-third had prior MI and diabetes mellitus. The majority came from rural areas with a low or middle socioeconomic status, and had a history of smoking. These patients with CAD showed relatively severe illness, had significant time delay from angina onset to admission or intervention, and rarely received the guidelines-recommended treatment.

At baseline, compared with SCAD, patients with ACS were younger, had higher plasma glucose and LDL cholesterol, had lower income and educational level, were more often current smoker, and had poorer dietary habits. Further, we observed considerably more patients with ACS with diagnosis/signs of heart failure, with left ventricle hypertrophy and with lower LVEF than patients with SCAD. Likely as a result, those with ACS had poorer clinical outcomes mainly during hospitalisation and at 30-day follow-up compared with those with SCAD.

In contrast, at 6-month follow-up, more patients with SCAD had adverse cardiac events compared with ACS (p= 0.043). The most likely explanation is that these patients with SCAD were undertreated for secondary prevention and aftercare management. Out of 113 patients with SCAD, 34 (30.1%) were admitted for congestive heart failure (CHF); and of 90 patients with SCAD with cardiac catheterisation, 58 (64.4%) had multivessel CAD. Of those, only 32 (55.2%) underwent elective PCI. Therefore, the lack access or adherence to the guidelines-recommended treatment (ie, elective PCI or CABG) and the lack of engagement to the long-term cardiovascular medications might largely contribute to these poorer outcomes. Meanwhile, in ACS, low access to an early invasive strategy was more likely to be associated with the high incidence of short-term death, chiefly in the first 30 days since admission.

In this study, we found that patients with ACS in Indonesia (mean age 57.5 years) were younger than patients with ACS in Japan (66.4 years)[@R20] and in the Global Registry of Acute Coronary Events (GRACE) from 14 countries (65 years),[@R21] but equally young with patients with ACS in Malaysia (58.1 years).[@R22] In these previous studies, the majority of patients were male (\>65%).[@R20]

Hypertension, diabetes and smoking are the top three risk factors responsible for 3.5 million deaths in South-East Asia every year, and particularly afflicting the young population.[@R2] In our ACS group, the proportions of hypertension (73.6% vs 47.1%) and diabetes mellitus (30.8% vs 15.6%) were higher than in a similar multicentre study of patients with acute MI in France.[@R23] The smoking-experience rate of patients with CAD in Indonesia (62.3%) was strikingly higher than in Japan (57.0%),[@R20] UK (53.4%)[@R19] and Malaysia (47.0%).[@R22] This finding is compatible with WHO Global Status Report in 2014.[@R4]

Asian populations are less obese than Western populations.[@R4] Despite a much lower prevalence of overweight or obesity (22%--26% in South-East Asia vs 67% in UK and 70% in USA), raised blood glucose/diabetes mellitus is a pivotal risk factor in South-East Asia, reaching similarly high prevalence with the UK and USA.[@R4] In contrast to the Western populations where diabetes is strongly associated with obesity, South-East Asia populations have a unique 'lean diabetic' phenotype.[@R4] In terms of lifestyles, patients with CAD in Indonesia have a poor dietary pattern as reflected by high intakes of sugar and deep-fried foods. Our cohort showed physical inactivity levels (58.1%) higher than the open population reported in Malaysia (51.6%), UK (40.0%) and USA (35.0%).[@R4]

Overall at hospital admission, these patients with CAD showed relatively severe clinical features, with more renal insufficiency and heart failure. Our findings are in line with a previous report that, compared with the Netherlands, patients with STEMI in Indonesia more often presented with severe illness with heart failure signs and had a longer time delay between symptom onset and hospital admission.[@R7] We found that the time lapse between symptom onset and admission was 24 (IQR 9--48) hours in patients with ACS. This was much longer compared with the GRACE study from 95 hospitals of 14 countries for patients with STEMI (139 (73--313) min), NSTEMI (190 (90--510) min) or for UA (180 (90--435) min).[@R21]

The time lapse from admission to intervention and length of stays were remarkably shorter in SCAD than in ACS group, because in our study the majority of referred patients (n=50, 71.4%) were classified as SCAD. These patients underwent an elective cardiac catheterisation and/or PCI and were then immediately returned to the referring hospitals. We did not track and record the duration of stay in the original hospitals. However, we assumed hospital stay duration in the referring hospitals to be relatively short because these patients usually underwent elective interventions for SCAD.

Longer time delay from the symptom onset to hospital admission remains one of the most crucial issues in cardiovascular services in the low-income and middle-income countries,[@R25] particularly in Indonesia. The prominent problems appeared from the patients side were the lack of awareness of precursor symptoms,[@R25] the negative perception and apprehension to the hospital, and financial problems.[@R26] On the other hand, clinicians delay in making an early diagnosis and treatment in primary hospital or clinic, lack of collaboration between hospitals and doctors, administrative barriers, transportation problems and lack of ambulance organisation[@R26] were also the influential factors for this extensive delay. Those who live in very remote areas, tend to manage their complaints with a visit to the local/traditional healer or non-traditional healthcare provider. As a result, there was a very low frequency of primary PCI and thrombolysis procedures conducted in our centre considering the 'golden time' period for effective reperfusion. A previous study reported that in the real-world practice, primary PCI as recommended by the guidelines is very difficult to perform in patients with STEMI in Indonesia; time delay is a critical issue for decision-making in choosing reperfusion strategy (primary PCI, fibrinolytic or the combination).[@R26]

We believed there are many unrecorded deaths due to CVD in this population because patients with more severe disease are likely to die before reaching the hospital and are not reported. This indicated that those with more stable and stronger physical endurance will have a chance to turn up alive in the hospital. We conclude that in general, haemodynamically unstable patients---for logistic reasons (ie, the lack of transportation, interventional cardiologist and cath lab capacity)---first had to be stabilised prior to a rather planned intervention. Evidently, the infrastructure and resources were not sufficient to deal with emergency CAG followed by rescue PCI to treat the patients with acute CVD.

From hospital admission to 6 months, 59 (16.2%) patients with ACS underwent primary or elective PCI. This is comparable with PCI following ACS in Malaysia (13%--17%),[@R27] but much lower than Japan (74%) and USA (71%--87%).[@R27] The total mortality rate at 30 days was 15.7% in patients with ACS ([figure 2](#F2){ref-type="fig"}), which is incredibly higher compared with patients in Japan (3.4%),[@R20] and in the US patients after PCI intervention (1.0%).[@R28] Meanwhile, 24 (6.6%) patients with ACS died between discharge and 6-month follow-up, and therefore higher than in the GRACE registry study (4.7%).[@R29]

Previous studies suggested that optimal revascularisation could prevent \~32% of deaths by 6 months,[@R27] and better 6-month survival was associated with the use of clopidogrel, statin and timely PCI or CABG.[@R27] Our data showed similar findings: the survival was significantly better in patients with statin, clopidogrel and revascularisation (PCI/CABG) compared with the non-guidelines-treated groups (see [figure 3](#F3){ref-type="fig"}).

Patients undergoing PCI for ACS have higher short-term and long-term mortality rates compared with those with SCAD undergoing elective PCI.[@R31] In our study, patients with revascularisation (PCI or CABG) in ACS and SCAD groups were not significantly different in terms of survival (p=0.236). However, when we compared the 6-month survival between patients with versus without revascularisation, there was an explicitly lower survival in those who did not undergo a revascularisation, both in ACS and SCAD groups (p=0.002) ([figure 3](#F3){ref-type="fig"}).

Despite the fact that over 80% of mortality from CVD occurs in low-income and middle-income countries,[@R32] these countries often do not have integrated primary healthcare programmes for early detection and treatments for cardiovascular risk factors to meet that challenge. In Indonesia, the poorest and very remote people are affected the most. Before the national health insurance era started in 2014, 80% of Indonesian people were uncovered by a sufficient health insurance.[@R7] Although the existing insurance schemes (Askes, Jamsostek, Jamkesmas and Jamkesda) conferred a large positive impact on access to healthcare facilities---notably for people from the low and middle socioeconomic level[@R33]still, the provided access to specific 'elitary treatments' were limited.[@R34]

Moreover, people who already suffered from CVD have also less access to an effective secondary prevention.[@R8] Geographical and regional distances, low awareness and support from family members, and financial constraints were most likely responsible for the lack of access to this aftercare rehabilitation. According to the guidelines also adopted in Indonesia, most of these patients were not appropriately treated. Therefore, the stakeholders in Indonesia should focus on the improvement of primary and secondary prevention. Promotion of healthy lifestyles should be well established in order to reduce the prevalence of cardiovascular risk factors. The dissemination of first aid management for acute CVD as well as a rapid and standardised in-hospital response has to be established.

Strengths and limitations {#s4a}
-------------------------

There are some strengths and limitations in the present study:We had to exclude all patients who immediately died at emergency department and cardiovascular intensive care unit because we could not obtain a written informed consent from this group with the most critically ill conditions.The majority of our patients (51.8%) were living in rural, often very remote areas. Hence, it was not possible to interview all patients by means of a face-to-face interview for follow-up. In 239 (50.1%) patients, phone calls were used, which may have led to less accurate data than obtained by direct questionnaire interview. However, we always verified the answers at the next visits or phone calls with a different interviewer to reduce inaccuracies.We excluded all patients with normal CAG, which were mostly females. Thus, our study may have overlooked the minor group of MI with no obstructive coronary atherosclerosis.Our study is, to our knowledge, the first in Indonesia with regard to clinical outcomes of hospitalised patients with CAD. Thus, we consider our study a quite unique effort to properly report on characteristics at admission and on short-term and mid-term outcomes in an attempt to identify opportunities to improve care.

Conclusions {#s5}
===========

Patients with CAD from a poor South-East Asian setting present themselves with predominantly unstable conditions of premature CAD. These patients show relatively severe illness, have significant time delay from symptom onset to admission or intervention, and most do not receive the guidelines-recommended treatment. Awareness of symptoms, prompt initial management of acute CVD, well-established infrastructures and resources both in primary and secondary hospital for CVD should be improved to reduce the high rates of 30-day and 6-month mortality and adverse outcomes in this population.
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